News
Exciting times are ahead in the next few years for the prurigo nodularis treatment market as it is projected to grow to $2.11 billion in 2029, marking a compound annual growth rate CAGR of 5.1%.
Original results from the phase 3 OLYMPIA 1 (NCT04501679) and 2 (NCT04501666) trials demonstrated the safety and efficacy of nemolizumab administered subcutaneously every 4 weeks in 560 patients ...
Ständer S, et al. IFSI-guideline on chronic prurigo including prurigo nodularis. Itch. 2020;5 (4):e42. doi: 10.1097/itx.0000000000000042 ...
Home NICE Guidance Conditions and diseases Infections Skin infections Nemolizumab for treating prurigo nodularis [ID6451] In development [GID-TA11566] Expected publication date: TBC Project ...
Prurigo Nodularis Companies are Trevi Therapeutics, Galderma, Genentech, Incyte Corporation, Vyne Therapeutics Inc., Celgene Corporation, Novartis, Pfizer, Regeneron ...
As Incyte strives to push its topical JAK inhibitor Opzelura into additional dermatology indications, the company’s latest data drop in prurigo nodularis carries a mix of both positives and negativ ...
This follows its approval for the treatment of adults with prurigo nodularis by the United States (U.S.) Food and Drug Administration (FDA) in August 2024. 14 Atopic dermatitis is a common, chronic, ...
Prurigo nodularis is a chronic, debilitating, and distinct neuroimmune skin disease characterized by the presence of intense itch and thick skin nodules covering large body areas. 6 The majority of ...
The global prurigo nodularis treatment market is poised for substantial growth, projected to reach a valuation of USD 693.3 million by 2023, according to a recent report by Future Market Insights. The ...
Kwatra SG, et al. Placebo-controlled phase III trial of nemolizumab in patients with prurigo nodularis. N Engl J Med. 2023;389:1579-89. doi: 10.1056/NEJMoa2301333 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results